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Summary.-The presence or absence of lymphocytic mucopolysaccharides (MPS)
is studied in 223 subjects: 100 normals (controls); 8 cancer patients cured for more
than 6 years; 30 cancer patients at the start of their treatment; and 85 relatives of
first degree consanguinity of these last patients. The data are studied by statistical
and genetic analysis. The results confirm the findings reported earlier and show
that the difference in the probability of a high frequency of leucocytic MPS between
the relatives of cancer patients and the controls is highly significant. Furthermore,
this probability in a relative of first degree of consanguinity of a cancer patient is
more than three times greater than in an individual of the general population.
Genetic segregationanalysis showsthatthehighleucocyticMPStrait segregatesinthe
families of cancer patients after a classic pattern of dominant autosomal inheritance.
Applying Falconer's nomogram it is concluded that the whole of this phenotypic
variation is of genetic origin. Its interrelationships with cancer are discussed and
it is postulated that this disturbance of the lymphocytic MPS represents a sub-
clinical variant, not known until now, of the clinical mucopolysaccaridoses.
IN a former study (Riesco and Leyton,
1971) one of us showed that the blood of
patients with cancer contained a much
higher proportion of leucocytes with acid
mucopolysaccharides (MPS) than that of
normal individuals, the difference between
both groups in this respect being statis-
ticallyextremelysignificant. Itwasestab-
lished that the presence or absence of
MPS in the leucocytes did not depend on
the cancer having been treated or not, at
least during periods before or shortly
after treatment.
In view of this it was important to
know whether the presence ofMPS in the
leucocytes ofthese patients was caused by
cancer in its clinical state. Therefore
we examined whether patients treated for
cancer more than 6 years before, and with
apparent clinical recovery, still showed
increased MPS in their leucocytes. The
leucocytic MPS were determined in 8
patients of this type, treated between 6
and 23 years previously (Table I). It
was found that the same leucocytic
alteration as in untreated cancer patients,
TABLE I.-Distribution of the Lymphocytes With and Without MPS in the Peripheral
Blood of 8 Cancer Patients Clinically Apparently Curedfor More Than 6 Years*
Peripheral lymphocytes
No. of A No. of lymphocytes
casest Positive °o Negative classified
Cervix carcinoma 5 24 24 76 100
Breast carcinoma 3 13 42 47 60
Total 8 37 23 123
* All patients with histopathological diagnosis of cancer.
t Time of follow-up of cases considered as clinically cured (time elapsed between end of treatment and
moment of leucocytic MPS study) was distributed thus: 6 years (2 cases), 7 years (1 case), 8 years (2 cases),
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or inthose treatedless than one yearbefore,
was present in these patients, though in a
lesser degree.
This new finding made it seem possible
that the increased MPS content in leuco-
cytes, instead of being a consequence of
cancer, might be an anomaly present in the
individual before the development of his
cancer. Furthermore, we suggested the
hypothesis that this leucocytic alteration
might be caused by a constitutional
anomaly based on a possibly geneticfactor.
To elucidate this possibility, we studied
the presence or absence of leucocytic
MPS and its genetic implication in a
group of cancer patients and their rela-
tives of first degree of consanguinity.
MATERIALS AND METHODS
The subjects of this study were 223
individuals. Thirty-eight were cancer
patients who had consulted during 1971 at
the Caupoliean Pardo Correa Institute
(National Health Service), all of them with
histopathological diagnosis of their neo-
plasms. One hundred were normal volun-
teers from blood donors at the Blood Bank of
the JoseJoaquinAguirre Hospital (University
of Chile), and comprised the control group.
Eight patients had been treated for cancer
6 or more years before and were clinically
cured (Table I). The other 30 patients
(Table II) had received no treatment or were
starting it. In the study were included
85 relatives of first degree of consanguinity
of these 30 patients, grouped in 30 families,
all presumably healthy, consisting of 6
parents, 32 siblings and 47 children of the
patients with cancer (Tables III and V). In
all of them the presence or absence of leuco-
cytic MPS was studied. The method em-
ployed was the same as in our former study
(Riesco and Leyton, 1971).
In every group the number of lympho-
cytes with or without MPS was compared
(Table III), as well as the number of subjects
TABLE II. Clinical Diagnosis of the 30 Cancer Patients* Propinquity of the 85
Relatives Included in the Studyt
Cases
Acute lymphoid leukaemia
Osteogenic sarcoma of the fibula
Sacro-iliac osteogenic sarcoma
Cutaneous carcinoma of the cheek
Carcinoma of the tonguie
Oesophageal carcinoma
Carcinoma of the breast
Carcinoma of endometiium
Cervix uterine carcinoma, stage I
Cervix uterine carcinoma, stage II
Cervix uterine carcinoma, stage III
Cervix uterine carcinoma, stage IN'
I
I
1
5
5
9o
* Six males an(l 24 females, all with histopathological confirmation of cancer.
t The 85 presumably healthy relatives of the 30 cancer patients were composed as follows: 6 parents
(5 mothers and one father), 47 chilclren (32 daughters and 15 sons), 32 siblings (22 sisters aind 10 brothers)-
TABLE III. Distribution of Lymphocytes With and Without MPS from the Peripheral
Blood of 30 Cancer Patients, 85 of their Presumably Healthy Relatives, and 100
Normal Control Subjects*
Group
Normal controls
Cancer patients
Parents healthy
Siblings healthy
Children healthy
Total of kindred
No. of
cases
100
30
6
32
47
85
Positix
215
345
56
194
281
531
Peripheral lymphocytes
ve % Ne}
10-75
47 - 50
46- 66
30-31
29- 89
31-23
gative
1785
255
64
446
659
1169
No. of lymphocytes
classified
2000
600
120
640
940
1700
* The statistical study of the data from this Table is shown in Table IV.
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TABLE IV.-The Increased Proportion of Lymphocytes Positive for MPS in Various
Groups ofSubjects Relative to their Controls
Pairs Proportion Ratio X2 P
Cancer patients
vs controls
Healthy parents
vs controls
Healthy siblings
vs controls
Healthy children
vs controls
Cancer patients
vs healthy parents
Cancer patients
vs healthy siblings
Cancer patients
vs healthy children
0 -575/0 - 107
0-466/0- 107
0 289/0 107
0-387/0- 107
0 575/0 466
0 575/0 289
0 575/0 367
5 37
4 35
2 70
3 61
1 23
1 98
1 56
570 6 < 0 000001
125 4 < 0*000001
141 0 < 0 00001
167 1 < 0-00001
4 75 >0 05
93 2 < 0 0001
115 9 < 0.0001
TABLE V. Study and Distribution of 215 Subjects Having a Normal or Abnormal
Number ofLymphocytes Without MPS (Group 0) in their Peripheral Blood*
Subjects with Subjects with
normal No. of abnormal No. of
lymphocytes lymphocytes Total No. of
Group without MPSt without MPS§ subjects
No . %
Normal
controls
Cancer
patients
Healthy
parents
Healthy
siblings
Healthy
children
Total healthy
relatives
78
14
20
37
22 22
23 77
3 50
18 36
27 57
48 56
100
30
6
32
47
85
* The statistical study of the data from this Table is shown in Table VI.
t A subject with a normal no. of lymphocytes without MPS is considered one in whom 18, 19 or 20
lymphocytes studied contain no MPS (Group 0).
§ A subject with an abnormal no. of lymphocytes wxithout MPS is considered one in whom 17 or less
of 20 lymphocytes studied contain no MPS (Group 0).
with normal or abnormal numbers oflvmpho-
cytes without MPS (Table V), and the results
were treated statistically (Tables IV, VI and
VII). In our former study (Riesco and
Leyton, 1971) we analysed comparatively
only the total number of lymphocytes with
and without MPS in each clinical group. In
the present study we also include the com-
parative analysis of the number of indivi-
duals with normal and subnormal numbers of
negative lymphocytes.
For determining the normal number of
negative lymphocytes in each individual in
the analysis of the group of 100 normal sub-
jects we applied two different approaches.
One, as shown in Table III, is that 89 25%
of the total lymphocytes of 100 normal sub-
jects are negative: in each individual 9000
of the 20 lymphocytes classified is 18, a
figure that represents the normal limit of
negative lymphocytes in each individual
according to this approach. On the other
hand, the study of the bimodal curve in the
same group of 100 normal subjects shows that
the antimode is located at 18 negative
lymphocytes (Fig. 1), between the majority
group (77%) and the minority (23%) of
negative lymphocytes. Both approaches for
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TABLE VI.-Statistical Study of the Data shown in Table V and Corresponding to
215 Subjects with Normal and Subnormal Number ofLymphocytes Without MPS
in their Peripheral Blood
Pairs N Ratio X2 P
Controls vs
cancer patients
Controls vs
healthy relatives
Cancer patients V8
healthy relatives
130 3 40
185 2-56
115 1*35
30 4 < 0*001
23*3 < 0*001
3-8 > 0-10
TABLE VII.-Segregation Analysis of the MPS Trait in 19 Families of Cancer
Patients in which One Patient was Affected
No. of MPS Cases
families observed expected
8
5
3
1
1
19
5
8
5
3
3
0
24
4
5
4.5
2
3
4
22-5
the determination of the normal number of
negative lymphocytes in an individual give
a limit of 18 normal out of 20.
Therefore, for the analysis of the subjects
of the study an individual is considered as
having a normal number ofnegative lympho-
cytes when (1) he has the same or a greater
percentage of negative lymphocytes than
that of the total negative lymphocytes of
100 normal individuals (I, II), or when (2)
he falls within the majority group of the
bimodal curve of individual -distribution
BIMODAL DISTRIBUTION OF 100 NORMAL
SUBJECTS ACCORDING TO THE NUMBER
OF NEGATIVE LYMPHOCYTES
24
22
20
18
16
14
12
10
8
6
4
21 *I, * l- lli..--:
69
I
of negative lymphocytes of 100 normal
subjects (Fig. 1), i.e., when ofthe 20 lympho-
cytes, classified 18, 19 or 20 lymphocytes are
negative (Group 0). An individual is con-
sidered as having a subnormal number of
negative lymphocytes when of the 20
lymphocytes classified, 17 or less lympho-
cytes are negative.
The genetic study of the MPS trait was
made by (a) segregation analysis by classic
methods (Smith, 1956); (b) analysis of
relative risks in the relatives of first degree
of consanguinity by the method of Li (1961).
The analysis of the positive or negative
MPS trait in the families studied included the
cancer patients. Segregation analysis was
irrespective of the distribution of the cancer
patients within the families.
RESULTS
The results of the study are summed
up in the Tables III and V. Table III
shows that the percentage oflymphocytes
without MPS in normal individuals
(89.25%) is markedly higher than in
cancer patients (42*50%), which supports
the results of our former study (Riesco
and Leyton, 1971). Table V shows an
even greater difference between the per-
centage of individuals with a normal
Sibship
size
1
2
3
4
6
8
Totals
Normal
cases
3
2
4
1
3
8
21
x2 =6-60 5/P = > 0-10
Total
cases
8
10
9
4
6
8
45
2
0-25
1 80
0 05
0 50
0*00
4*00
6-60
w
V)
U
LL
0.
z
2 3 4 5 6 7 8 9 101112 13 14 15 16 17 1819 20
N_ OF LYMPHOCYTES WITHOUT MPS
.
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number of lymphocytes without MPS
in the control group (78.0%) and in the
cancer patients (23.33%). The statis-
tical stuidy ofthese differences gave figures
of highest significance. They were
X2 570 7 for the lymphocytes without
MPS and x2 - 30X4 for the individuals
with a normal number of lymphocytes
without MPS (Tables IV' and VI).
The 83 relatives, presumably healthy,
of the 30 cancer patients had 68-76% of
lymphocyteswithoutMPS, against 8925 %0
for the lvmphocytes of the 100 control
subjects (Table III), and had a proportion
of abnormal lymphocytes almost three
times that of the controls. Table V
shows ain even greater difference in the
percentage of subjects with a normal
number of lymphocytes without MPS
betmeen the controls (78.00%) and the 85
relatives of the cancer patients (43.52%).
The statistical study of these differences
also show%-ed a high significance (Table VI).
An extremely high significance was also
found for the differences between the
number of lymphocytes without MPS in
the control group and in the healthy
relatives of the cancer patients, in the
parents (X2- 141.0), as well as in the
offspring (X2 -167X1) of these patients
(Table IV). Lastly, as can be seen in
Table VI, there is a significant difference
in the frequency of individuals with a
normal number of lymphocytes without
MPS between controls and cancer patients
as well as between controls and the healthy
relatives of these patients, but there is no
significant differenceinthisrespect between
cancer patients and their presumably
healthy- relatives.
The statistical study of the increased
proportion of leucocytic MPS in the
families of cancer patients is given in
Table IV, which shows that this propor-
tion is 5*37 times greater in cancer
patienits than in controls. The com-
parison between the proportion in patients
and in controls is also statistically signi-
ficant. The differences in proportion
decrease between cancer patients and their
relatives, and there is no significant
difference between the patients and their
parents. Table VI gives the results ofthe
statistical treatment of the data from
Table V and confirms that the incidence
of lymphocytic MPS is not significantly
different between cancer patients and
their relatives, whereas the differences
become highly significant when controls
and relatives of cancer patients are
compared.
The genetic analysis of segregation of
the leucocytic MPS-positive trait in the
30 families studied is shown in Table VII.
In 16 families the leucocytic MPS-positive
trait was present in 2 generations: parent
and offspring. In the other 14 it was not
possible to study both parents. For this
genetic analysis the parent-offspring rela-
tionship is studied irrespective of whether
the cancer patient is parent, sibling or
offspring. According to the rule of domi-
nance, in the 85 offspring studied (59
daughters and 26 sons), half of them,
i.e. 42-5, should be affected. The results
of the present study show that the
affected offspring number 50, a figure not
significantly different from the expected
one. In consequence, the results reported
here are compatible with the proposed
hypothesisthattheleucocyticMPS-positive
trait appears in the families of cancer
patients in the classic pattern ofdominant
autosomal inheritance.
DISCUSSION
The genetic study of the distribution
of the leucocytic MPS phenotype in the
families of cancer patients revealed the
presence of that trait in all generations.
The trait appeared in autosomal dominant
pattern according to the rule ofdominance
in all of the families. Segregation analy-
sis, the results of which are shown in
Table VII, corroborated the empirical
impression that the MPS phenotype
segregates in the families of cancer
patients in a way compatible with an
autosomal dominant trait.
When the genetic study of the leuco-
cytic MPS is analysed using quantitative
genetics after the method of Li (1961), it
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becomes apparent that the relatives of
cancer patients carry a very high probabi-
lity of having the MPS phenotype, which
does not significantly differ from the risk
of cancer patients compared with the
controls. This indicates that the genetic
factor of leucocytic MPS is quantitatively
very powerful. The probability of posi-
tive MPS for a normal, non-cancerous
individual who is a first degree relative
of a cancer patient is more than 3 times
greater than in an individual ofthe general
population. Speaking in terms of heri-
tability and applying Falconer's nomo-
gram (1965), for a frequency of positive
MPS of 220% in the general population,
a frequency of 56% in the relatives offirst
degree of consanguinity indicates 110%
of heritability. All the families assessed
in the present study live in the same
oncological environment as the rest of the
general population. Therefore, a heri-
tability greater than 100% suggests that
the whole of the phenotypic variation is
of genetic origin.
The gene for a high level of leuco-
cyte MPS would be dominant with full
penetrance, thus supporting the inter-
pretation of the segregation analysis.
These results imply that the increase
in leucocytic MPS would be pre-existent
and not caused by cancer.
The existence of certain other clinical
disturbances of high magnitude of the
MPS, not connected with cancer (also of
genetic nature but of recessive type,
called mucopolysaccharidoses, (McKusick,
1969), leads us to speculate on the
possibility that the alteration in leuco-
cytic MPS which we have described
represents a variant of these disorders of
lesser, subclinical magnitude. This sub-
clinical entity, more frequent than the
clinical mucopolysaccharidoses, would be
apparently asymptomatic and for the
moment its detection is possible only
through the cytochemical study of the
leucocytes in the peripheral blood.
The already reported interrelation-
ships of this subclinical entity with cancer
and tuberculosis (Riesco and Leyton,
1971), confirmed here in relation to cancer,
are still not sufficiently clear. However,
if their presence is actually related with
antineoplastic immunology, as has been
suggested (Riesco and Leyton, 1971),
the findings presented here would be of
value for a better definition of the
population with high cancer risk. The
results do not provide factors that might
help to elucidate this hypothesis.
The present genetic study must be
regarded as preliminary to an extension
of the investigation of the leucocytic
MPS phenotype in families of the general
population. As it is, these preliminary
results undoubtedly suggest the possi-
bility of using this phenotype as a new
genetic marker associated in a statistically
highly significant way with the prevalence
of cancer.
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